Tyra Biosciences’ (TYRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $30.00 target price on the stock.

Several other equities analysts have also issued reports on TYRA. UBS Group began coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Trading Down 0.1 %

Shares of Tyra Biosciences stock opened at $12.78 on Tuesday. The firm has a market capitalization of $646.67 million, a PE ratio of -7.94 and a beta of 1.05. The business’s 50-day moving average price is $14.51 and its 200-day moving average price is $18.23. Tyra Biosciences has a 12 month low of $11.89 and a 12 month high of $29.60.

Insiders Place Their Bets

In related news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the sale, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds have recently made changes to their positions in TYRA. Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $56,716,000. Boxer Capital Management LLC bought a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $28,185,000. Janus Henderson Group PLC bought a new stake in Tyra Biosciences in the third quarter worth $24,994,000. Farallon Capital Management LLC bought a new stake in Tyra Biosciences in the fourth quarter worth $13,914,000. Finally, Vestal Point Capital LP bought a new stake in Tyra Biosciences in the fourth quarter worth $13,761,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.